Bank of New York Mellon
ARQT icon

Bank of New York Mellon’s Arcutis Biotherapeutics ARQT Stock Holding History

Bank of New York Mellon’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.66M Buy
330,094
+24,562
+8% +$572K ﹤0.01% 2106
2026
Q1 		$7.2M Buy
305,532
+1,104
+0.4% +$28.2K ﹤0.01% 2110
2025
Q4 		$8.84M Sell
304,428
-6,192
-2% -$159K ﹤0.01% 1994
2025
Q3 		$5.86M Buy
310,620
+5,362
+2% +$84.6K ﹤0.01% 2231
2025
Q2 		$4.28M Buy
305,258
+5,227
+2% +$73.3K ﹤0.01% 2366
2025
Q1 		$4.69M Sell
300,031
-4,976
-2% -$70.1K ﹤0.01% 2258
2024
Q4 		$4.25M Sell
305,007
-6,052
-2% -$66.3K ﹤0.01% 2379
2024
Q3 		$2.89M Sell
311,059
-79,143
-20% -$781K ﹤0.01% 2573
2024
Q2 		$3.63M Buy
390,202
+80,078
+26% +$724K ﹤0.01% 2487
2024
Q1 		$3.07M Sell
310,124
-7,803
-2% -$58.2K ﹤0.01% 2545
2023
Q4 		$1.03M Buy
317,927
+80,148
+34% +$218K ﹤0.01% 3175
2023
Q3 		$1.26M Buy
237,779
+27,170
+13% +$231K ﹤0.01% 3035
2023
Q2 		$2.01M Buy
210,609
+74,454
+55% +$826K ﹤0.01% 2829
2023
Q1 		$1.5M Buy
136,155
+4,782
+4% +$69.2K ﹤0.01% 2949
2022
Q4 		$1.94M Buy
131,373
+6,764
+5% +$118K ﹤0.01% 2865
2022
Q3 		$2.38M Buy
124,609
+29,182
+31% +$661K ﹤0.01% 2738
2022
Q2 		$2.03M Sell
95,427
-919
-1% -$18.9K ﹤0.01% 2824
2022
Q1 		$1.86M Sell
96,346
-1,177
-1% -$19.9K ﹤0.01% 2975
2021
Q4 		$2.02M Buy
97,523
+2,459
+3% +$48.9K ﹤0.01% 2990
2021
Q3 		$2.27M Buy
95,064
+7,985
+9% +$182K ﹤0.01% 2915
2021
Q2 		$2.38M Buy
87,079
+178
+0.2% +$5.01K ﹤0.01% 2881
2021
Q1 		$2.51M Buy
86,901
+20,374
+31% +$636K ﹤0.01% 2793
2020
Q4 		$1.87M Buy
66,527
+9,916
+18% +$243K ﹤0.01% 2887
2020
Q3 		$1.66M Buy
56,611
+21,356
+61% +$571K ﹤0.01% 2773
2020
Q2 		$1.07M Buy
35,255
+11,171
+46% +$323K ﹤0.01% 3076
2020
Q1 		$718K Buy
+24,084
New +$647K ﹤0.01% 3191

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's ARQT Position: Q2 2026 in Review

Bank of New York Mellon increased its Arcutis Biotherapeutics (ARQT) stake by 8% in Q2 2026, buying an estimated $572K and bringing the position to 330,094 shares worth $8.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

Bank of New York Mellon first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.84M in Q4 2025. 139 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Bank of New York Mellon held 330,094 shares of Arcutis Biotherapeutics worth $8.66M as of Q2 2026.
  • Bank of New York Mellon bought 24,562 Arcutis Biotherapeutics shares in Q2 2026, an estimated $572K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2106 holding.
  • Bank of New York Mellon first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Bank of New York Mellon's Arcutis Biotherapeutics position peaked at $8.84M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.